Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more
Moleculin Biotech Inc (MBRX) - Total Assets
Latest total assets as of September 2025: $20.35 Million USD
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) holds total assets worth $20.35 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Moleculin Biotech Inc - Total Assets Trend (2015–2024)
This chart illustrates how Moleculin Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Moleculin Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Moleculin Biotech Inc's total assets of $20.35 Million consist of 30.7% current assets and 69.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.3% |
| Accounts Receivable | $20.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.15 Million | 65.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Moleculin Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Moleculin Biotech Inc's current assets represent 30.7% of total assets in 2024, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 25.3% of total assets in 2024, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 65.9% of total assets.
Moleculin Biotech Inc Competitors by Total Assets
Key competitors of Moleculin Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Moleculin Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Moleculin Biotech Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Moleculin Biotech Inc is currently not profitable relative to its asset base.
Moleculin Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 2.08 | 5.89 |
| Quick Ratio | 1.39 | 2.08 | 5.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.20 Million | $ 6.01 Million | $ 14.28 Million |
Moleculin Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Moleculin Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 476.20 |
| Latest Market Cap to Assets Ratio | 1.33 |
| Asset Growth Rate (YoY) | -55.7% |
| Total Assets | $16.93 Million |
| Market Capitalization | $22.47 Million USD |
Valuation Analysis
Above Book Valuation: The market values Moleculin Biotech Inc's assets above their book value (1.33 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Moleculin Biotech Inc's assets decreased by 55.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Moleculin Biotech Inc (2015–2024)
The table below shows the annual total assets of Moleculin Biotech Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $16.93 Million | -55.71% |
| 2023-12-31 | $38.22 Million | -33.45% |
| 2022-12-31 | $57.42 Million | -31.71% |
| 2021-12-31 | $84.09 Million | +188.37% |
| 2020-12-31 | $29.16 Million | +15.55% |
| 2019-12-31 | $25.23 Million | +28.85% |
| 2018-12-31 | $19.59 Million | +0.52% |
| 2017-12-31 | $19.48 Million | +18.85% |
| 2016-12-31 | $16.39 Million | +58256.54% |
| 2015-12-31 | $28.09K | -- |